Hydroxyurea (hydroxycarbamide)

General description

Hydroxyurea (also known as hydroxycarbamide) is used in the management of sickle cell disease, and in treatment protocols for chronic myeloproliferative disorders.

INN	Hydroxycarbamide
ATC codes	L01XX05
Medicine type	Chemical agent
EML status history	First added in 2009 (TRS 958) for Chronic myeloid leukaemia, not elsewhere classified Changed in 2009 (TRS 958) for Squamous cell carcinoma of oropharynx Changed in 2011 (TRS 965) for Other specified sickle cell disorders or other haemoglobinopathies Removed in 2015 (TRS 994) for Squamous cell carcinoma of oropharynx
Wikipedia	Hydroxyurea (hydroxycarbamide)
DrugBank	Hydroxycarbamide (Hydroxyurea)

Recommendations

Section Cytotoxic medicines

- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

Chronic myeloid leukaemia, not elsewhere classified

Squamous cell carcinoma of oropharynx

Section Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies